stocks logo

TYRA

Tyra Biosciences Inc
$
11.060
+0.28(2.597%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
11.230
Open
10.790
VWAP
10.96
Vol
213.80K
Mkt Cap
588.15M
Low
10.4355
Amount
2.34M
EV/EBITDA(TTM)
--
Total Shares
52.54M
EV
269.21M
EV/OCF(TTM)
--
P/S(TTM)
--
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
Show More
6 Analyst Rating
up Image
173.06% Upside
Wall Street analysts forecast TYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TYRA is 30.20 USD with a low forecast of 28.00 USD and a high forecast of 33.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
up Image
173.06% Upside
Current: 11.060
sliders
Low
28.00
Averages
30.20
High
33.00
Piper Sandler
Allison Bratzel
Overweight
initiated
$33
2025-05-21
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$30
2025-03-31
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$30
2025-02-18
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$30
2025-01-13
Reason
UBS
Eliana Merle
Strong Buy
Initiates
$28
2025-01-07
Reason
UBS analyst Eliana Merle initiated coverage of Tyra Biosciences with a Buy rating and $28 price target. Tyra Biosciences is a clinical-stage biotech company with a drug, TYRA-300, in development for bladder cancer and a genetic form of short stature, achondroplasia, with many health complications, the analyst tells investors in a research note. The firm thinks TYRA-300 could have improved efficacy and safety vs. Fibroblast Growth Factor Receptor inhibitors that also inhibit FGFR1, 2 and 4, and thinks the long-term opportunity for TYRA-30 in both oncology and growth disorders beyond achondroplasia is larger than appreciated.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Maintains
$32 → $30
2024-11-11
Reason

Valuation Metrics

The current forward P/E ratio for Tyra Biosciences Inc (TYRA.O) is -4.83, compared to its 5-year average forward P/E of -8.90. For a more detailed relative valuation and DCF analysis to assess Tyra Biosciences Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.90
Current PE
-4.83
Overvalued PE
-4.27
Undervalued PE
-13.54

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.42
Current EV/EBITDA
-1.92
Overvalued EV/EBITDA
13.24
Undervalued EV/EBITDA
-20.08

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
YoY :
+42.68%
-31.85M
Operating Profit
FY2025Q1
YoY :
+54.72%
-28.15M
Net Income after Tax
FY2025Q1
YoY :
+34.29%
-0.47
EPS - Diluted
FY2025Q1
YoY :
+14.93%
-25.47M
Free Cash Flow

Trading Trends

Insider
Insiders areSelling! The selling amount has increased 745.3% over the last month.
Sold
0-3
Months
628.3K
USD
5
3-6
Months
74.3K
USD
1
6-9
Months
2.5M
USD
10
0-12
Months
5.7M
USD
14
Bought
0-3
6
15.3M
USD
Months
3-6
0
0.0
USD
Months
6-9
1
19.8M
USD
Months
0-12
1
151.9K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
717.0K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
1
1.8M
Volume
Months
3-6
2
3.8M
Volume
Months
6-9
4
3.3M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

TYRA News & Events

Events Timeline

2025-06-30 (ET)
2025-06-30
08:07:34
Tyra Biosciences says first patient dosed in Phase 2 study of TYRA-300
select
2025-05-08 (ET)
2025-05-08
16:21:54
Tyra Biosciences reports Q1 EPS (47c), consensus (48c)
select
2025-05-06 (ET)
2025-05-06
14:14:54
Oncology stocks 'bearing the brunt' of Prasad news, says Oppenheimer
select
Sign Up For More Events

News

1.0
07-21PRnewswire
Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
9.0
07-08PRnewswire
Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025
4.0
07-01Benzinga
HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target
Sign Up For More News

FAQ

arrow icon

What is Tyra Biosciences Inc (TYRA) stock price today?

The current price of TYRA is 11.06 USD — it has increased 2.6 % in the last trading day.

arrow icon

What is Tyra Biosciences Inc (TYRA)'s business?

arrow icon

What is the price predicton of TYRA Stock?

arrow icon

What is Tyra Biosciences Inc (TYRA)'s revenue for the last quarter?

arrow icon

What is Tyra Biosciences Inc (TYRA)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Tyra Biosciences Inc (TYRA)'s fundamentals?

arrow icon

How many employees does Tyra Biosciences Inc (TYRA). have?

arrow icon

What is Tyra Biosciences Inc (TYRA) market cap?